Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - General

Sanofi India Limited manufactures and trades in drugs and pharmaceutical products in India, Singapore and internationally. The company provides pharmaceutical products in various therapeutic areas, such as diabetes, cardiology, thrombosis, infections, central nervous system, anti-infectives, epilepsy, allergy and vitamins, and minerals and supplements, as well as pain care and nutritional health under the Lantus, Toujeo, Clexane, Amaryl, Cardace, Glimepiride, Cetapin, Targocid, Frisium, Combiflam, DePura, Allegra, and Avil brands through independent distributors. It also exports its products to approximately 35 countries. The company was formerly known as Aventis Pharma Limited and changed its name to Sanofi India Limited in May 2012. The company was incorporated in 1956 and is headquartered in Mumbai, India. Sanofi India Limited is a subsidiary of Hoechst GmbH.

Revenue projections:

Revenue projections for SANOFI
Revenue projections for SANOFI

Revenues for SANOFI are forecasted to decline from last year's levels, prompting caution among investors. When revenues fall, it can have a significant negative impact on the company's bottom line, reducing profitability and making the stock less attractive to risk-averse investors.

Financial Ratios:

currentRatio 0.00000
forwardPE 18.73939
debtToEquity 2.37600
earningsGrowth -0.14100
revenueGrowth -0.11900
grossMargins 0.49036
operatingMargins 0.28329
trailingEps 134.61000
forwardEps 179.06667

Sanofi India Limited's Forward PE is in a favorable range, meaning its stock price compares well with its earnings and isn't overpriced. This leaves room for growth, making it a compelling opportunity for investors looking to benefit from potential future gains.
SANOFI's low growth in both earnings and revenue indicates a likely decrease in profits. This suggests the company may be facing financial challenges, and investors should be cautious about its future performance.
Sanofi India Limited's positive gross and operating margins reflect strong financial performance. These metrics indicate that the company is efficiently managing its operations and generating healthy profits, contributing to a solid financial position.
SANOFI's forward EPS surpassing its trailing EPS signals projected growth in profitability, with the company expected to perform better this year. This forecast suggests that SANOFI's earnings will improve compared to the previous financial year, highlighting optimism in its financial outlook.

Price projections:

Price projections for SANOFI
Price projections for SANOFI

The current valuation of Sanofi India Limited, concerning its projections, presents no apparent risks or opportunities. This neutral outlook may lead investors to adopt a cautious approach as they await further insights into the company's performance.

Recommendation changes over time:

Recommendations trend for SANOFI
Recommendations trend for SANOFI


The analysts' outlook on Sanofi India Limited remains mixed, with no clear buy or sell ratings. This ambiguous stance could signal uncertainty for investors, suggesting the need for additional research and market analysis before making any firm decisions regarding the stock.